Journal Watch · Nature Communications · 2026

Modifying muscle metabolic dysregulation in inclusion body myositis with pioglitazone: a single-arm trial.

Clinical Trials Registration: NCT03440034.

Adler BL, Bene MR, Zhang C et al.Nature Communications3 min readPharma relevance 85/100

DOI: 10.1038/s41467-026-70262-0PMID: 41832158Study type: randomised / controlled clinical trial

TL;DR

Clinical Trials Registration: NCT03440034.

Key findings

  • As a phase 1 trial with a limited cohort, these findings provide preliminary evidence that pioglitazone modulates muscle metabolism and warrants further investigation in IBM.
  • This study was supported by the Ira T.
  • Discovery Fund and the Peter and Carmen Lucia Buck Foundation Myositis Discovery Fund.
  • Clinical Trials Registration: NCT03440034.

Numbers at a glance (from the abstract)

p = 0.099

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

At baseline, muscle metabolomics revealed broad metabolic abnormalities compared with controls. Pioglitazone reversed elements of this signature, increasing PPARGC1A expression (p = 0.099) and modulating downstream pathways in muscle, including enhanced oxidative phosphorylation. Clinical outcomes were unchanged overall, but a subset with favorable metabolic responses showed slower decline in the IBM-Functional Rating Score (IBM-FRS) and Modified Timed Up and Go (m-TUG). Reported adverse effects included myalgia and heart failure exacerbation.

Full abstract (original)

Background: This single-arm, open-label phase 1 trial evaluated the PPARγ agonist pioglitazone in patients with inclusion body myositis (IBM). After a 16-week observation (lead-in) period, participants received pioglitazone 45 mg daily for 32 weeks. The primary outcome was the change in PPARGC1A expression and related metabolic pathways in muscle after 16 weeks of treatment compared with the lead-in period. Of the 16 enrolled participants, 13 initiated pioglitazone and completed at least one on-treatment assessment; the trial was terminated early due to the COVID-19 pandemic.

What they did: At baseline, muscle metabolomics revealed broad metabolic abnormalities compared with controls. Pioglitazone reversed elements of this signature, increasing PPARGC1A expression (p = 0.099) and modulating downstream pathways in muscle, including enhanced oxidative phosphorylation. Clinical outcomes were unchanged overall, but a subset with favorable metabolic responses showed slower decline in the IBM-Functional Rating Score (IBM-FRS) and Modified Timed Up and Go (m-TUG). Reported adverse effects included myalgia and heart failure exacerbation.

Results & conclusions: As a phase 1 trial with a limited cohort, these findings provide preliminary evidence that pioglitazone modulates muscle metabolism and warrants further investigation in IBM. This study was supported by the Ira T. Discovery Fund and the Peter and Carmen Lucia Buck Foundation Myositis Discovery Fund. Clinical Trials Registration: NCT03440034.

Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-70262-0 · PubMed 41832158.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Nature Communications study find?

Clinical Trials Registration: NCT03440034.

What type of study is this?

It is a randomised / controlled clinical trial, published in Nature Communications in 2026. At baseline, muscle metabolomics revealed broad metabolic abnormalities compared with controls.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41467-026-70262-0. PubMed ID: 41832158. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Adler BL, Bene MR, Zhang C et al.. Modifying muscle metabolic dysregulation in inclusion body myositis with pioglitazone: a single-arm trial.. Nature Communications (2026). DOI: 10.1038/s41467-026-70262-0.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/modifying-muscle-metabolic-dysregulation-in-inclusion-body-myositis-with-702620/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides